-
CluePoints sponsored RBQMLive 2026 will explore shift from adoption to operational maturity.
Sep 30, 2026
-
Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it has been chosen as a strategic sequencing partner for Florida’s Sunshine Genetics Pilot Program and will serve as the lead sequencing provider at launch.
Oct 4, 2026
-
CellCarta and Imagene AI today announced an expanded collaboration to provide a coordinated path for biopharma companies to validate, deploy, and scale AI-powered biomarker and companion diagnostic programs.
Sep 30, 2026
-
ViewsML, a leader in AI-powered virtual biomarker staining, today announced the appointment of Michael Rivers to its Board of Directors. Rivers brings more than 20 years of experience leading the commercialization of global diagnostic and digital pathology portfolios, including experience advancing AI-enabled technologies from development through regulatory clearance and market adoption.
Sep 28, 2026
-
Data shows priming agents improved sensitivity for disease detection and mutational profiling while preserving key cfDNA features.
Sep 21, 2026
-
Leading Phoenix urology practice adopts advanced AI cancer mapping to personalize surgical planning, enhance patient visualization, and pave the way for outpatient treatments
Sep 21, 2026
-
The expanded panel pairs the industry’s largest-ever marker count with methodology upgrades designed to give practitioners and patients the most comprehensive view of mold exposure yet, supporting more informed clinical decisions.
Sep 21, 2026
-
Sep 21, 2026
-
IQVIA MedTech is highlighting its Surgical Collaboration Platform, designed to help MedTech organizations coordinate and scale surgeon-to-surgeon education. The platform brings surgeon requests, credentialing, faculty matching, scheduling, documentation, training completion and reporting into a connected workflow as increasingly sophisticated medical technologies create greater demands on clinician education.
Sep 21, 2026
-
Sep 22, 2026
-
Sep 15, 2026
-
Reckitt plans to invest up to $600 million across New Jersey and North Carolina to strengthen U.S. R&D, innovation and OTC manufacturing. The investment will create a new science and innovation center and expand its largest U.S. OTC facility to support Mucinex, Move Free and future healthcare product demand.
Sep 16, 2026
-
Sep 15, 2026
-
IQVIA MedTech has launched Data Device Link (DDL), a new capability that connects patient-level data generated by medical devices and diagnostics with longitudinal healthcare data to provide a broader view of the patient journey. By linking device and diagnostic data with sources such as claims, prescriptions, laboratory data and electronic health records, DDL is designed to help manufacturers generate real-world evidence, evaluate outcomes and support regulatory and post-market research.
The announcement also highlights real-world applications of this approach, including the use of data linkage to address missing demographic information for an FDA representativeness assessment and the development of a post-market registry supporting five years of patient outcomes monitoring.
Sep 15, 2026
-
The FDA's historic psychedelic hearing highlighted a critical question: how can psychedelic medicines become accessible without compromising patient safety? As developers move closer to potential approvals, regulators must balance clinical evidence, professional oversight, workforce training, geographic access and long-term safety.
Sep 14, 2026
-
Qinecsa has been selected as technology partner for AfriVigilance, the African Medicines Agency’s new continent-wide medicines safety surveillance platform, with implementation already underway.
Sep 9, 2026
-
AstraZeneca’s Etcamah has received FDA accelerated approval for ctDNA-guided treatment in HR-positive, HER2-negative breast cancer with ESR1 mutations. The decision could establish an earlier treatment-switch strategy based on molecular changes before cancer becomes visible on scans.
Sep 9, 2026
-
Sakura Finetek Europe today announced the launch of the Sakura Pathology Network (SPN), a new European network bringing together early-career pathologists from across Europe.
Sep 9, 2026
-
Biocon has secured a 10-year PDP allocation for pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis, covering around 70% of the country’s public-sector demand.
The agreement combines long-term supply with phased local production, supporting affordable cancer treatment access and strengthening Brazil’s domestic biopharmaceutical capabilities.
Sep 7, 2026
-
Comprehensive pharmacogenetic testing solution aligned with latest clinical guidance to support informed chemotherapy treatment decisions
Sep 7, 2026